|
PIK3C2B expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 7.957800E-02 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.332560E-01 |
| Normal-vs-Stage2 |
8.227800E-02 |
| Normal-vs-Stage3 |
3.696200E-03 |
| Normal-vs-Stage4 |
1.119110E-03 |
| Stage1-vs-Stage2 |
5.635800E-04 |
| Stage1-vs-Stage3 |
6.239800E-02 |
| Stage1-vs-Stage4 |
1.416070E-02 |
| Stage2-vs-Stage3 |
4.1991000000019E-05 |
| Stage2-vs-Stage4 |
1.57007000000098E-05 |
| Stage3-vs-Stage4 |
4.054800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.072000E-02 |
| Normal-vs-AfricanAmerican |
5.283800E-02 |
| Normal-vs-Asian |
1.567600E-02 |
| Caucasian-vs-AfricanAmerican |
4.953200E-01 |
| Caucasian-vs-Asian |
3.145200E-01 |
| AfricanAmerican-vs-Asian |
9.507400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.541200E-01 |
| Normal-vs-Female |
2.546400E-02 |
| Male-vs-Female |
1.379570E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.496200E-02 |
| Normal-vs-Age(41-60Yrs) |
7.944500E-02 |
| Normal-vs-Age(61-80Yrs) |
5.268000E-01 |
| Normal-vs-Age(81-100Yrs) |
8.512100E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.654000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.104400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.651800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.135200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.171000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.249400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.0362000002484E-07 |
| Classical-VS-Follicular |
2.578100E-04 |
| Classical-VS-Other |
3.136600E-01 |
| Classical-VS-Normal |
5.617600E-02 |
| Tall-VS-Follicular |
2.19729789918688E-11 |
| Tall-VS-Other |
2.782600E-01 |
| Tall-VS-Normal |
4.82899999987296E-08 |
| Follicular-VS-Other |
4.614100E-02 |
| Follicular-VS-Normal |
3.524800E-01 |
| Other-VS-Normal |
6.124100E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.825600E-01 |
| Normal-vs-N1 |
4.03270000000067E-05 |
| N0-vs-N1 |
2.05340000003496E-06 |
|
|
